Global epidemiology, risk factors, and histological types of ovarian cancers in Trinidad
- PMID: 31041251
- PMCID: PMC6482720
- DOI: 10.4103/jfmpc.jfmpc_384_18
Global epidemiology, risk factors, and histological types of ovarian cancers in Trinidad
Abstract
Background: Ovarian cancer is the seventh most common cancer in women in the world and Trinidad and Tobago is ranked 18th in the world with respect to the rate of occurrence. About 68% cases are diagnosed at a late stage, resulting in low survival rates. Since there is very scanty literature available on the epidemiology of ovarian cancer in the Caribbean region, this study was undertaken to assess the most common risk factors, presenting symptoms and common histological varieties in Trinidad.
Methods: A hospital-based, cross-sectional study was designed, and all the 23 diagnosed ovarian cancer cases registered during 2015-2017 were considered. Information on sociodemographics, presenting symptoms, and histological type of cancers were collected after getting the ethical approval. Of the total 23 cases, 17 cases were included in this study after ensuring completeness of data as detailed analysis of patient data was done using Microsoft Excel.
Results: The common risk factors identified were previous pregnancies, previous surgeries, and irregularities in the menstrual cycle. The commonest histological variety was granulosa tumors and the most common associated symptoms were irregular menses and abdominal pain in premenstrual women, and abdominal distention in postmenopausal women.
Conclusions: It would greatly enhance the detection rate if screening and testing for the CA-125 gene were a mandatory practice, for any patient found with more than three risk factors. The public health authorities should identify the modifiable risk factors and implement cancer reduction and health promotion activities to reduce the mortality related to ovarian cancers.
Keywords: Cross-sectional design histology hormone replacement therapy; ovarian cancer; risk factors; serous carcinoma.
Conflict of interest statement
There are no conflicts of interest.
Figures
Similar articles
-
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.Oncologist. 1996;1(5):326-330. Oncologist. 1996. PMID: 10388011
-
Epidemiology of ovarian cancers in Zaria, Northern Nigeria: a 10-year study.Int J Womens Health. 2017 Nov 22;9:855-860. doi: 10.2147/IJWH.S130340. eCollection 2017. Int J Womens Health. 2017. PMID: 29200893 Free PMC article.
-
A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.Breast Cancer Res Treat. 2019 Apr;174(2):469-477. doi: 10.1007/s10549-018-5045-y. Epub 2018 Dec 4. Breast Cancer Res Treat. 2019. PMID: 30515680
-
Overview of resistance to systemic therapy in patients with breast cancer.Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.
-
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.Fam Cancer. 2004;3(3-4):265-81. doi: 10.1007/s10689-004-9554-y. Fam Cancer. 2004. PMID: 15516851 Review.
Cited by
-
Breast cancer in Trinidad and Tobago: Etiopathogenesis, histopathology and receptor study.J Family Med Prim Care. 2021 Dec;10(12):4438-4445. doi: 10.4103/jfmpc.jfmpc_627_21. Epub 2021 Dec 27. J Family Med Prim Care. 2021. PMID: 35280639 Free PMC article.
-
The Correlation of Papanicolaou Smears and Clinical Features to Identify the Common Risk Factors for Cervical Cancer: A Retrospective and Descriptive Study from a Tertiary Care Hospital in Trinidad.Vaccines (Basel). 2023 Mar 18;11(3):697. doi: 10.3390/vaccines11030697. Vaccines (Basel). 2023. PMID: 36992281 Free PMC article.
-
Comorbidities and inflammation associated with ovarian cancer and its influence on SARS-CoV-2 infection.J Ovarian Res. 2021 Feb 25;14(1):39. doi: 10.1186/s13048-021-00787-z. J Ovarian Res. 2021. PMID: 33632295 Free PMC article. Review.
-
In Vitro Assessment of Magnetic Liposomal Paclitaxel Nanoparticles as a Potential Carrier for the Treatment of Ovarian Cancer.Adv Pharm Bull. 2021 Feb;11(2):267-273. doi: 10.34172/apb.2021.039. Epub 2020 Aug 5. Adv Pharm Bull. 2021. PMID: 33880348 Free PMC article.
References
-
- American Cancer Society, Key Statistics for Ovarian Cancer. [Last accessed on 2018 Oct 11]. Available from: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html .
-
- World Cancer Research Fund International. Ovarian cancer statistics. World Cancer Research Fund International [Internet] [cited 2016 Nov 5]; Available from: http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/ovari... .
-
- James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858. - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous